Completed

Antidepressant Treatment of AIDS Related Depression.

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Imipramine hydrochloride

Drug
Who is being recruted

Depression

From 18 to 65 Years
+8 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 2
Interventional

See protocol details

Summary

Principal SponsorGEIGY Pharmaceuticals
Last updated: April 23, 2015
Sourced from a government-validated database.Claim as a partner

To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride. To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Official TitleAntidepressant Treatment of AIDS Related Depression. 
Principal SponsorGEIGY Pharmaceuticals
Last updated: April 23, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 18 to 65 YearsRange of ages for which participants are eligible to join.
Conditions
Pathology
Depression
Criteria
4 inclusion criteria required to participate
Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented
May have been alcoholic or drug abuser 6 months previous
Unspecified
CD4 Unspecified
4 exclusion criteria prevent from participating
Non ambulatory patients or those requiring extensive help in self care are excluded
Non ambulatory patients or those requiring extensive help in self care are excluded
Current alcohol or drug abuse
Unspecified
Anonymus Profile Image
Ensure optimum compatibilityAdd your profile to know your probability eligibility score.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
New York Hosp - Cornell Med CtrNew York, United StatesSee the location
CompletedOne Study Center
Antidepressant Treatment of AIDS Related Depression. | PatLynk